0.000
0.00 (0.00%)
| Harga / Jualan (P/S) | 14.62 |
| Harga / Buku (P/B) | 24.41 |
| Margin Keuntungan | -27.70% |
| Margin Operasi (TTM) | -27.50% |
| EPS Cair (TTM) | -2.51 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 55.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -99.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 208.50% |
| Nisbah Semasa (MRQ) | 2.80 |
| Aliran Tunai Operasi (OCF TTM) | -145.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.78 M |
| Pulangan Atas Aset (ROA TTM) | -9.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -47.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Blueprint Medicines Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 1.00 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.88% |
| % Dimiliki oleh Institusi | 109.19% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |